Cargando…
The powerful world of antisense oligonucleotides: From bench to bedside
Antisense oligonucleotides (ASOs) represent a new and highly promising class of drugs for personalized medicine. In the last decade, major chemical developments and improvements of the backbone structure of ASOs have transformed them into true approved and commercialized drugs. ASOs target both DNA...
Autores principales: | Quemener, Anaïs M., Bachelot, Laura, Forestier, Anne, Donnou‐Fournet, Emmanuelle, Gilot, David, Galibert, Marie‐Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285911/ https://www.ncbi.nlm.nih.gov/pubmed/32233021 http://dx.doi.org/10.1002/wrna.1594 |
Ejemplares similares
-
Antisense oligonucleotide: A promising therapeutic option to beat COVID‐19
por: Quemener, Anaïs M., et al.
Publicado: (2021) -
Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology
por: Amanat, Man, et al.
Publicado: (2022) -
Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development
por: Quemener, Anais M., et al.
Publicado: (2022) -
Non-canonical miRNA-RNA base-pairing impedes tumor suppressor activity of miR-16
por: Quéméner, Anaïs M, et al.
Publicado: (2022) -
Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)